Chemomab Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	16	6	37	79	13	10
Market Cap Growth	-37.02%	-82.85%	-53.12%	512.83%	23.57%	-
Enterprise Value	1	-13	-3	18	2	-6
PE Ratio	-	-0.26	-1.33	-6.30	-2.16	-0.38
PB Ratio	1.24	0.37	1.02	1.28	1.19	0.70
P/FCF Ratio	-	-0.27	-1.80	-6.77	-2.43	-0.63
P/OCF Ratio	-	-0.27	-1.81	-6.36	-2.45	-0.63
EV/EBITDA Ratio	-	0.54	0.10	-1.43	-0.26	0.27
EV/EBIT Ratio	0.23	0.54	0.10	-1.43	-0.26	0.27
EV/FCF Ratio	-	0.56	0.14	-1.54	-0.30	0.37
Debt / Equity Ratio	0.03	0.02	0.01	0.01	0.04	0.07
Debt / EBITDA Ratio	-	-0.02	-0.01	-0.03	-0.07	-0.05
Debt / FCF Ratio	-	-0.02	-0.01	-0.03	-0.08	-0.07
Quick Ratio	3.83	4.32	6.18	23.66	9.00	4.26
Current Ratio	3.83	4.32	6.18	23.66	9.00	4.42
Interest Coverage	-	-	-	-	-	-5.42
Return on Equity (ROE)	-109.90%	-114.00%	-58.20%	-20.00%	-66.40%	-219.50%
Return on Assets (ROA)	-83.70%	-88.50%	-52.50%	-19.00%	-52.50%	-166.80%
Return on Capital (ROIC)	-149.10%	-146.41%	-78.31%	-20.01%	-53.18%	-142.89%
Earnings Yield	-117.27%	-382.86%	-74.96%	-15.86%	-46.36%	-261.12%
FCF Yield	-373.26%	-55.41%	-14.76%	-41.13%	-159.35%
Buyback Yield / Dilution	-28.58%	-3.26%	-9.70%	-51.71%	-1488.06%	-172.65%
Total Shareholder Return	-28.58%	-3.26%	-9.70%	-51.71%	-1488.06%	-172.65%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).